1. Introduction {#sec0001}
===============

Posterior Cortical Atrophy (PCA) is a rare neurodegenerative condition, very often associated with Alzheimer\'s disease (AD) pathology ([@bib0031]; [@bib0032]; [@bib0037]). Previous studies have explored the patterns of gray matter (GM) atrophy, the distribution of hypoperfusion and hypometabolism, as well as the presence of white matter (WM) damage and functional connectivity alterations in PCA ([@bib0001]; [@bib0010]; [@bib0023]; [@bib0025]; [@bib0026], [@bib0027], [@bib0028]; [@bib0029], [@bib0030]; [@bib0033]). Altogether, these studies have shown that in PCA patients brain damage is focal and posterior ([@bib0023]; [@bib0027]; [@bib0033]) and WM pathways involvement highly contributes to the clinical profile ([@bib0010]; [@bib0026], [@bib0028], [@bib0029]). They have also highlighted functional connectivity alterations, in particular in the visual and default mode networks ([@bib0001]; [@bib0025]; [@bib0030]). In some cases, functional magnetic resonance imaging (fMRI) studies suggested the existence of possible functional compensatory mechanisms supported, in particular, by the relatively intact anterior brain regions ([@bib0001]; [@bib0030]).

In the last years, the brain connectivity field has largely turned to graph (or network) theory, an analytic language for describing complex networks ([@bib0009]). Graph analysis is a new way to unravel the complexity of structural and functional bases of clinical and cognitive decline in neurodegeneration and it provides a more detailed analysis than the classic resting state fMRI approaches. Nevertheless, very few studies have explored structural and functional connectome properties in early onset AD ([@bib0016]; [@bib0025]), and no studies are available for focal AD patients (e.g., PCA).

In the present study, the main objective is to identify functional connectome abnormalities in patients affected by PCA. We predict a highly diffuse pattern of network alterations at both global and regional level, more centered on posterior brain regions, and characterized by a focal disconnectivity mainly involving intrahemispheric posterior-anterior connections. We also expected that anterior brain regions would be spared and potentially able to compensate posterior functional brain alterations.

In addition to this, two ancillary analyses available as supplementary material will be performed. In order to understand better underlying pathophysiological mechanisms, a first analysis explored the connectomic features according to the cerebrospinal fluid (CSF) AD profile of PCA patients. In a previous study, Montembeault et al. showed that PCA patients have different anatomo-functional presentations in relation to different CSF AD profiles ([@bib0031]). Second, given that brain hypometabolism is usually wider than atrophy ([@bib0007]; [@bib0031]) and thus to avoid losing information related to brain damage, we will combine MRI and fluorodeoxyglucose (FDG)-positron emission tomography (PET) explorations in a small subset of patients to corroborate the main hypothesis and assess functional connectivity of hypometabolic, atrophic and spared brain areas.

2. Methods {#sec0002}
==========

2.1. Participants and study design {#sec0003}
----------------------------------

Eighteen PCA patients and 29 age-matched healthy subjects without history of neurological or psychiatric diseases (22/7 women/men; mean age = 63.3 ± 5.3 years; mean education = 12.8 ± 2.3 years; mean Mini-Mental State Examination \[MMSE\] = 28.5 ± 1.7) participated in this study. Clinical and cognitive data were acquired at the centre National de Référence "Démences Rares", located at the "Institut de la mémoire et de la maladie d\'Alzheimer" (IM2A), in the Pitié-Salpêtrière Hospital, Paris. Medical records of patients clinically diagnosed with PCA were reviewed by a neurologist (R.M.) and a neuropsychologist (M.M.) to confirm they met PCA diagnostic criteria. Diagnosis of PCA was mainly based on recently proposed clinical classification ([@bib0012]); specifically on: 1) presentation with progressive visual or visuospatial impairment in the absence of ophthalmologic impairment; 2) evidence of complex visual disorder on examination (elements of Balint\'s and Gerstmann\'s syndrome, visual agnosia, alexia, apraxia, or environmental disorientation); 3) proportionately less memory loss (i.e., patients were required to present with early complaints of visual and visuospatial impairment in the absence of major memory complaints). Exclusion criteria for this study were left-handedness, history of other neurological or psychiatric diseases, ophthalmologic disease, early and predominant extrapyramidal symptoms or signs, hallucinations, cognitive fluctuations, rapidly evolving dementia syndromes, or signs of substantial leukoencephalopathy on MRI, in particular in the occipito-parietal regions, at presentation. The study was approved by the local committee on human research. All subjects provided written informed consent before participating.

All patients underwent a neuropsychological battery including a global cognitive assessment with MMSE ([@bib0017]) as well as an assessment of "frontal" brain functions with the frontal assessment battery (FAB) ([@bib0015]), backwards digit span ([@bib0041]), and word generation tasks for category and letter fluency ([@bib0024]). Patients' scores on these tests were compared between groups with Kruskall-Wallis tests (*p* ≤ 0.05). A more detailed exploration of "posterior" brain functions, through a battery specifically conceived for PCA patients and previously described ([@bib0030]) and applied ([@bib0023]; [@bib0028], [@bib0029], [@bib0030]; [@bib0031]), was also administered. This battery was designed to investigate "dorsal" deficits such as elements of Balint\'s and Gerstmann\'s syndromes, motor apraxia, ideomotor apraxia and visual neglect, as well as "ventral" deficits such as alexia and visual agnosia. Patients were classified as impaired or not impaired on these symptoms. Percentage of impaired subjects were compared between groups with Fisher\'s exact test of independence (*p* ≤ 0.05) and, given the sample size. Healthy controls underwent a neurological evaluation and the MMSE. For ancillary analyses, PCA patients were also classified according with their CSF AD profile as: 1) PCA with a typical CSF AD profile (PCA-tAD); 2) PCA with an atypical AD CSF profile (PCA-aAD); and 3) PCA not associated with AD (PCA-nonAD) (see supplementary material).

2.2. MRI study {#sec0004}
--------------

### 2.2.1. MRI acquisition and pre-processing {#sec0005}

#### 2.2.1.1. MRI protocol {#sec0006}

Brain MRI scans were acquired with a 3T system (Siemens, Erlangen, Germany) at the Center for Magnetic Resonance Research (CENIR), Brain and Spine Institute (ICM), Paris. A high-resolution structural volume was acquired using a T1-weighted 3D magnetization prepared rapid gradient echo (MP-RAGE) sequence (160 sagittal images; thickness 1 mm; field of view 256×256 mm^2^; matrix size 256×256). The functional images were acquired at rest by T2\*-weighted fast echo planar imaging (flip angle = 90◦, echo time = 30 ms, repetition time = 2.26 s, 45 interleaved axial slices, gap = 0.3 mm, voxel size = 3 × 3 × 3 mm^3^, acquisition time=8 min=). During RS fMRI scanning, subjects were instructed to remain motionless, to keep their eyes closed, and to not think about anything in particular. Fat saturation was performed to avoid chemical shift artifacts. All slices were positioned to run parallel to a line that joins the most inferoanterior and inferoposterior parts of the corpus callosum.

#### 2.2.1.2. Structural mri pre-processing {#sec0007}

Structural images were preprocessed using voxel-based morphometry (VBM) implemented in SPM12 using MATLAB 7.14.0.739 (Mathworks, Natick, MA). The images were segmented into GM and white matter. Affine registered tissue segments were used to create a custom template using the DARTEL (diffeomorphic anatomical registration using exponentiated lie algebra) approach ([@bib0002]). For each participant, the flow fields were calculated during a template creation, which described the transformation from each native GM image to the template. These were then applied to each participant\'s GM image. The VBM analysis was based on modulated GM images, where the GM value for each voxel was multiplied by the Jacobian determinant derived from spatial normalization to preserve the total amount of GM from the original images ([@bib0003]). The resulting modulated and normalized images were then smoothed with a Gaussian kernel of 8 mm FWHM. Statistical analysis was performed on smoothed GM images. First, GM maps were compared between all PCA patients and controls using an ANOVA model adjusting for subject\'s age, sex, and total intracranial volume (*p*\<0.05, FWE-corrected). The linear contrasts all PCA (*n* = 18) vs healthy subjects (*n* = 29) was set in order to identify differences in GM volume and was replicated on a smaller subset of six PCA with both structural MRI and FDG-PET ([Fig. 1](#fig0001){ref-type="fig"}A). A significance threshold of *p* ≤ 0.05 corrected for multiple comparisons (family-wise error) was accepted when comparing the larger group of patients vs. controls and of *p* ≤ 0.001 uncorrected when comparing the smaller group of six patients vs. controls.Fig. 1**Voxel-based morphometry and voxel-based metabolism results showing patterns of atrophy (A) and hypometabolism (B) in six PCA patients relative to 15 healthy controls.** Results are shown in neurological convention (right is right) at *p*\<0.001, uncorrected. Color bars (red to yellow) denote t values. Abbreviations: *L*= left; *R*= right (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.).Fig. 1

#### 2.2.1.3. Brain parcellation {#sec0008}

Brain was parcellated into 220 similarly-sized regions, as previously described ([@bib0016]). The registrations between subject\'s T1-weighted image and MNI152 standard space (linear and non-linear using FLIRT and FNIRT, respectively, as implemented in FSL \[FSLv5.0.9; <http://www.fmrib.ox.ac.uk/fsl>\]) and between subject\'s RS fMRI and T1-weighted images (linear registration as implemented in FLIRT) were calculated and concatenated in order to move the 220 GM ROIs into the subject\'s RS fMRI space.

#### 2.2.1.4. RS fMRI data pre-processing {#sec0009}

RS fMRI were pre-processed using the Statistical Parametric Mapping software package (SPM12; <http://www.fil.ion.ucl.ac.uk/spm/>) running on Matlab 7.6 and FSL. None of the study participants were excluded from analysis because of motion. The first part of the pre-processing was performed using FSL and included: (i) removal of the first four volumes to allow for signal equilibration; (ii) minor head movement correction by volume-realignment to the middle volume using MCFLIRT; (iii) removal of nonbrain tissue. Linear detrending and band-pass filtering between 0.01 and 0.08 Hz were performed using the REST software (<http://resting-fmri.sourceforge.net/>) to partially remove low-frequency drifts and physiological high-frequency noise. Using REST, non-neuronal sources of synchrony between RS fMRI time series and motion-related artifacts were minimized by regressing out the six motion parameters estimated by MCFLIRT, and the average signals of the ventricular cerebrospinal fluid and white matter.

#### 2.2.1.5. Functional brain network construction {#sec0010}

Functional connectivity matrices were obtained on the basis of correlation analysis. Mean time series were extracted from each ROI by averaging the signal from all voxels within each region. RS fMRI data were masked with subject\'s GM map in order to consider only voxels corresponding to GM and avoid the effect of atrophy. Cortical GM was segmented using SPM12, while basal ganglia (i.e., bilateral caudate, globus pallidus, putamen, and thalamus), hippocampus and amygdala maps were obtained using FIRST in FSL. The Pearson\'s correlation coefficient between the mean time-series of each ROI pair, indicating the level of functional connectivity between regions *i* and *j*, was enter into cell *c*(*i,j*) of the matrix. Pearson\'s correlation coefficients were then converted to z-scores using Fisher\'s r-to-z transformation. Negative correlation coefficients were set to 'not a number' to mark these brain regions as unconnected ([@bib0039]). An undirected, weighted graph describing the brain\'s network functional layout was obtained by computing correlations between the 220 GM ROIs. Functional connections were required to be present in a structural connectivity matrix of an independent healthy control sample (*N* = 90, mean age 62.3 ± 8.07 years, 51 women/39 men), i.e., we measured functional interactions only where an anatomical connection between two areas occurs in the independent healthy control sample, as previously reported ([@bib0016]).

### 2.2.2. fMRI analyses {#sec0011}

#### 2.2.2.1. Global and lobar functional brain network analysis {#sec0012}

Global and mean lobar network characteristics were explored using the Brain Connectivity Matlab toolbox (<http://www.brain-connectivity-toolbox.net>) as previously described ([@bib0016]). Network metrics, including clustering coefficient, characteristic path length, mean network strength, and local efficiency were assessed to characterize the global topological organization of global brain and lobar networks ([@bib0036]; [@bib0040]). In order to investigate the network characteristics in different areas of the brain, 220 regions of interest (ROIs) from both hemispheres were grouped into six anatomical macro-areas (hereafter referred to as lobes): fronto-insular, occipital, temporal, parietal, basal ganglia, and sensorimotor areas. Global and local metrics were compared between groups using age-adjusted ANOVA models, followed by post-hoc pairwise comparisons, Bonferroni-corrected for multiple comparisons (*p*\<0.05, SPSS Statistics 21.0).

#### 2.2.2.2. Regional functional connectivity analysis {#sec0013}

Network Based Statistics (NBS) ([@bib0016]; [@bib0018]; [@bib0042]) were performed to compare regional functional connectivity network data (in terms of Pearson\'s correlation coefficients) between groups at the level of significance *p*\<0.05. The largest (or principal) connected component and the smaller clusters of altered connections, which were not included in the principal connected component ([@bib0016]; [@bib0018]; [@bib0042]) were studied. A corrected p value was calculated for each component using an age-adjusted permutation analysis (10,000 permutations), as suggested by Zalesky and colleagues ([@bib0042]).

### 2.2.3. Network analysis within atrophic, hypometabolic and spared nodes {#sec0014}

The contrasts used for the VBM analyses were replicated with the same parameters for the PET analyses. Details for the FDG-PET study are available in the supplementary materials. The linear contrasts PCA vs. healthy subjects was set in order to identify differences in the metabolism ([Fig. 1](#fig0001){ref-type="fig"}B). Voxel based atrophy and hypometabolism maps were extracted from the comparison between the six PCA patients and 15 healthy subjects with both imaging scans. Based on atrophy and hypometabolism maps at *p*\<0.001 uncorrected ([Fig. 1](#fig0001){ref-type="fig"}), we defined each of the 220 ROIs (i.e., nodes) as atrophic only, hypometabolic only, atrophic *and* hypometabolic, and spared (nor atrophic neither hypometabolic). Each node was assigned to a category when at least the 50% of its total volume is included in a specific map (atrophic, hypometabolic, or both). Non-classifiable nodes were included in the "spared" group. Mean graph analysis metrics were investigated in each category of nodes. In addition, in order to assess connectivity among node categories, both inter- and intra-hemispherically, we measured the connectivity weight (CW) for each pair of node classes (NC) of the two hemispheres (NCx,NCy): CW(NCx,NCy)=∑\_(iϵNCx,jϵNCy) w~ij~, where w~ij~ is the connectivity weight between regions i and j. NCCW values were compared between groups by means of t-test setting the level of significance at *p*\<0.05 using NBS ([@bib0016]; [@bib0018]; [@bib0042]). A corrected p value was calculated for each pair of node classes using an age-adjusted permutation analysis (10,000 permutations).

3. Results {#sec0015}
==========

3.1. Clinical, cognitive and biological results {#sec0016}
-----------------------------------------------

Patients and controls were similar in terms of age (*p* = 0.82), sex distribution (*p* = 0.14), and education (*p* = 0.26). Overall, PCA patients presented mild-to-moderate global cognitive impairment with pathological scores at MMSE, FAB, letter and category fluencies, verbal and spatial spans, as well as typical visual symptoms that are characteristic of PCA ([Table 1](#tbl0001){ref-type="table"}).Table 1Demographic, biological, clinical and cognitive characteristics of PCA patients according with their cerebrospinal Alzheimer status at the time of imaging acquisition.Table 1All PCA patientsPCA-tAD (*n* = 9)PCA-aAD (*n* = 6)PCA-nonAD (*n* = 3)Difference between PCA subgroups**Demographics**Age (mean ± SD)63.3 (5.3)61.7 (5.9)63.5 (1.8)67.5 (7.5)n.s.Age range53--7553--6961--6661--75Education14.4 (2.7)15.5 (1.7)13.3 (2.9)13.7 (4.2)n.s.Sex (M/F)8/102/74/22/1n.s.Disease duration (years; mean ± SD)4.1 (2.2)3.1 (2.2)5.9 (1.7)3.6 (1.1)n.s.MMSE (mean ± SD)19.6 (5.0)17.3 (4.6)20.7 (3.4)24.3 (6.0)n.s.Aβ~1-42~ (pg/ml)381.5 (262.9)288.7 (72.3)291.0 (106.2)810.7 (417.3)*p* = 0.028\*P-Tau (pg/ml)70.9 (29.9)89.3 (29.8)49.4 (9.7)51.3 (12.5)*p* = 0.002\*T-Tau (pg/ml)495.2 (268.9)649.8 (287.7)310.6 (86.9)339.0 (56.7)*p* = 0.006\***Neuropsychological assessment**Frontal assessment battery (FAB)11.1 (2.8)10.2 (3.4)12.3 (0.8)11.3 (3.2)n.s.Verbal span backwards2.9 (1.0)2.9 (1.3)2.7 (0.8)3.3 (0.6)n.s.Spatial span backwards1.5 (1.5)1.3 (1.1)1.7 (1.4)1.7 (2.9)n.s.Phonemic fluency14.2 (7.7)10.7 (7.4)17.6 (6.7)19.0 (7.0)n.s.Category fluency13.4 (7.2)9.4 (5.9)17.3 (3.9)17.7 (11.0)n.s.**Symptoms (% of impaired patients)**n.s.Balint syndromen.s. Ocular apraxia35%25%50%33%n.s. Optic ataxia56%44%67%67%n.s. Simultagnosia94%89%100%100%n.s.Gerstmann syndromen.s. Acalculia72%78%83%33%n.s. Agraphia72%78%67%67%n.s. Finger agnosia56%67%33%67%n.s. Right-left disorientation44%44%50%33%n.s.Motor apraxia61%67%50%67%n.s.Ideomotor apraxia83%78%100%67%n.s.Visual neglect94%89%100%100%n.s.Alexia83%67%100%100%n.s.Visual agnosia88%89%80%100%n.s.[^1][^2][^3]

Detailed demographics, cognitive and CSF characteristics of each PCA patient are also shown in [Table 1](#tbl0001){ref-type="table"}. No significant difference was observed between groups of patients except for the disease duration, which tended to be slightly longer in PCA-aAD cases.

3.2. Imaging results {#sec0017}
--------------------

### 3.2.1. Structural study {#sec0018}

All PCA patients presented with the classic pattern of cortical atrophy centered on posterior brain regions including the occipital, parietal and posterior temporal regions. Scattered additional areas of atrophy were also present in more anterior and lateral frontal regions ([Fig. 1](#fig0001){ref-type="fig"}A).

### 3.2.2. Main study: connectome alterations in all PCA patients {#sec0019}

Relative to controls, PCA patients showed severe global functional network alterations (lower mean nodal strength, local efficiency, and clustering coefficient, and longer mean path length) (supplementary Table 2). The analysis of lobar network properties in PCA compared with controls showed a prominent involvement of the parietal, temporal, occipital and sensorimotor areas (alterations of all graph analysis metrics) ([Fig. 2](#fig0002){ref-type="fig"}; Supplementary Table 1). Furthermore, relative to controls, PCA patients showed a longer mean path length in the fronto-insular lobe and basal ganglia, and reduced clustering coefficient in the basal ganglia ([Fig. 2](#fig0002){ref-type="fig"}; Supplementary Table 1). At the regional connectivity level (NBS), compared to controls, PCA patients showed widespread functional connectivity reductions in intrahemispheric occipito-parieto-temporal pathways, but also in the frontal, parieto-frontal, temporo-frontal, basal ganglia-frontal connections bilaterally (*p*\<0.0024; [Fig. 3](#fig0003){ref-type="fig"}). PCA patients also showed functional connectivity reductions in interhemispheric pathways linking medial parietal nodes and basal ganglia (*p*\<0.0024; [Fig. 3](#fig0003){ref-type="fig"}).Fig. 2**Graph analysis properties of brain lobar networks in healthy controls and PCA patients**. Mean values of nodal strength, path length, local efficiency, and clustering coefficient of each brain lobe for healthy controls and PCA patients. Error bars are shown. \**p*\<0.05 in PCA versus healthy controls (see Supplementary Table 1 for further details). The direct comparison between PCA patients and healthy controls was adjusted for age. Abbreviations: HC= healthy controls; PCA= posterior cortical atrophy.Fig. 2Fig. 3**Affected functional connections in PCA patients relative to healthy controls (Network Based Statistic).** Subnetworks showing reduced functional connectivity in PCA patients relative to healthy controls are shown. The direct comparison between PCA patients and healthy controls was adjusted for age. The principal connected component is represented in red, the other affected connections not included in the principal connected component are shown in green. Supplementary Table 4 reports the names of each brain node with the corresponding number. Abbreviations: *L*= left; *R*= right.Fig. 3

### 3.2.3. Supplementary studies: connectome alterations in PCA according to their CSF AD profile {#sec0020}

Globally, PCA-tAD patients showed a reduced clustering coefficient relative to controls ([Table 1](#tbl0001){ref-type="table"}). PCA-aAD and PCA-nonAD patients did not demonstrate difference compared to healthy controls ([Table 1](#tbl0001){ref-type="table"}). Global graph analysis properties did not differ between patient groups ([Table 1](#tbl0001){ref-type="table"}). For more details see supplementary material.

### 3.2.4. Supplementary studies: connectome alterations in PCA within atrophic, hypometabolic and spared nodes {#sec0021}

Based on atrophic and hypometabolic maps, we identified hypometabolic only, hypometabolic *and* atrophic, and spared nodes (Supplementary Table 4). No nodes were classified into the atrophic only category. Irrespectively of the categorization, all node classes showed lower mean nodal strength, local efficiency, and clustering coefficient, and longer mean path length relative to healthy controls ([Fig. 4](#fig0004){ref-type="fig"}; Supplementary Table 5). Moreover, we observed a widespread loss of both intra- and inter-hemispheric functional connections between hypometabolic only, hypometabolic *and* atrophic, and spared nodes. No alterations were observed in the connections among spared areas ([Fig. 5](#fig0005){ref-type="fig"}).Fig. 4**Graph analysis properties of atrophic, hypometabolic and spared nodes in healthy controls and PCA patients**. Mean values of nodal strength, path length, local efficiency, and clustering coefficient of each node categories for healthy controls and PCA patients. Error bars are shown. \**p*\<0.05 in PCA versus healthy controls (see Supplementary Table 5 for further details). The direct comparison between PCA patients and healthy controls was adjusted for age. Abbreviations: HC = healthy controls; PCA= posterior cortical atrophy.Fig. 4Fig. 5**Intra- and inter-node categories connectivity weights (CW) in healthy controls and PCA patients.** The figure shows the hypometabolic, atrophic *and* hypometabolic, and spared nodes in different colors arranged as a ring (hypometabolic=violet, atrophic *and* hypometabolic=red and spared nodes=pink). The size of each sector of the ring is proportional to the number of brain nodes included in each category (see Supplementary Table 4 for further details). White lines indicate decreased CW in PCA relative to controls. A more detailed spatial distribution of the brain nodes is shown using sagittal and axial brain sections. Within this, each node is coloured according to the category it belongs to. The direct comparison between PCA patients and healthy controls was adjusted for age. Abbreviations: HC= healthy controls; *L*= left; PCA= posterior cortical atrophy; *R*= right (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.).Fig. 5

4. Discussion {#sec0022}
=============

Using graph analysis and a connectomic approach, we revealed a diffuse pattern of functional network alterations at both global and regional cerebral level in patients with PCA. As expected, the pattern was more centered on posterior brain regions. However, and against our prediction, it also involved less impaired anterior regions such as frontal and sensorimotor areas bilaterally. In particular, the intra-hemispheric functional connections were diffusely impaired, including those in frontal lobes. The inter-hemispheric connections were also severely impaired but particularly between posterior brain areas.

Parietal, occipital, temporal and sensorimotor nodes were preferentially affected ([Fig. 1](#fig0001){ref-type="fig"}), and this pattern is in agreement with previous classic fMRI studies exploring visual and non-visual networks in PCA ([@bib0001]; [@bib0025]; [@bib0030]). However, more anterior regions already show important signs of alteration, and when we studied the functional connections among nodes ([Fig. 2](#fig0002){ref-type="fig"}), we found that also the more anterior (frontal) pathways were already impaired in PCA. In particular, the intra-hemispheric parieto-frontal and fronto-frontal connections were found to be altered. Previous classic fMRI studies in atypical and focal AD ([@bib0025]; [@bib0030]) have showed hyperconnectivity in more anterior, apparently spared, brain regions possibly suggesting an attempt of network compensation. However, other fMRI studies on typical AD ([@bib0013]) and mild cognitive impairment ([@bib0004]) rather suggest that states of functional hyperconnectivity, which can later progress to hypoconnectivity, may indicate an early phase or the progression of brain dysfunction. Present graph-analysis and connectomics results strongly support this last interpretation. In particular, since the disease duration was of 4 years in average, we can conclude that the functional alterations indicate a progression of the disease.

Clinically, these results can explain some of the manifestations such as visuospatial attention deficits, visual agnosia and alexia, which are due to an anatomo-functional disconnection between distant - involved and spared- brain regions. In particular, the right parieto-frontal network is implicated in the visuospatial attention ([@bib0029]), while the ventral occipito-temporal network in the left hemisphere are implicated in object naming and reading ([@bib0028]). Moreover, ideomotor apraxia can arise, at least in part, from an inter-hemispheric disconnection from the left parietal lobe and contralateral homologous areas ([@bib0019]). Finally, our PCA patients showed pathological scores in tests as such FAB, verbal fluencies and the working memory spans, which are related to the frontal functioning. These cognitive deficits in PCA patients are very often neglected and/or considered as the result of major visual problems. This is partially true for visual spans and some FAB subtest in which the visual component is preponderant, but it is not valid for example for verbal fluencies or verbal span. These deficits, even if less important than the posterior symptoms, are most likely related to an early and genuine frontal dysfunction that we have finally confirmed with our approach.

The involvement of sensorimotor cortices and basal ganglia identified in our PCA patients can be interpreted in different ways: as the result of an early functional deficit in a region that is typically affected later in the disease, and/or as due to the presence of other neurodegenerative process in the sample of patients with a nonAD CSF biomarkers profile. For instance, the damage of sensorimotor cortices and basal ganglia has been well described in corticobasal degeneration patients ([@bib0008]). In some cases, patients with a corticobasal degeneration may clinically present as a PCA ([@bib0031]; [@bib0037]).

Taken together, these findings suggest the potentially high sensitivity of graph-analysis and connectomics in capturing signs of neurodegeneration progression in these patients and highlight the significance of applying network analysis to uncover how the brain connectivity interacts for example with the disease progression.

In order to better understand pathophysiological mechanisms associated with our results, we preliminarily explored the functional data according to CSF AD profiles. PCA group with both abnormal amyloid and T-tau/P-tau biomarkers showed more extensive functional connectivity alterations, while PCA group characterized by an isolated abnormal amyloid showed a focal connectivity impairment of the parietal lobes. Although the small number of patients in each CSF subgroup did not allow to reach salient conclusions, they highlight the importance to combine biological and imaging explorations to stratify patients with dementia.

Moreover, one might speculate that atrophy does not correspond to the real extent of damage and that hypometabolism provides more reliable information. For this reason, we combined MRI and FDG-PET evaluations to corroborate the main findings of our study. Most importantly, all the nodes, including those that were neither atrophic nor hypometabolic (spared), showed altered graph analysis properties ([Fig. 4](#fig0004){ref-type="fig"}). Moreover, the study of the connections among the different nodes showed both intra-hemispheric and inter-hemispheric breakdown between pathological nodes, and between pathological and spared nodes ([Fig. 5](#fig0005){ref-type="fig"}). Those results may suggest that the functional neuronal deficit precedes both structural and metabolic damage.

The study has some limitations. In terms of the clinical/cognitive assessment, some cognitive functions were only computed as binary variables (impaired/unimpaired) and some more ventral functions were not systematically explored, such as the facial identification ([@bib0034]). Furthermore, not all patients underwent the FDG-PET scan, which lead to a small sample size for that specific analysis. However, this analysis was performed to confirm the main results and to suggest new research prospective of multimodal imaging in PCA and more generally in dementia patients. Finally, none of our subjects had postmortem pathological diagnosis confirmation, which could be particularly interesting in disentangling the differences between PCA-tAD and PCA-aAD.
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[^1]: *n.s.= non-significant*.

[^2]: *p* values refer to Kruskall-Wallis test (*p* ≤ 0.05).

[^3]: Abbreviations: MMSE= mini mental state examination; PCA= posterior cortical atrophy; PCA-aAD= with atypical profile; PCA-nonAD= with normal profile; PCA-tAD= posterior cortical atrophy with typical cerebrospinal fluid Alzheimer\'s disease biomarkers profile.
